Koselugo（司美替尼selumetinib)

MEK inhibitors (mitogen activation inhibitors) are gradually being used in clinical applications. They can first be used to treat chronic pain, inhibit cancer cell proliferation, and treat non-small cell lung cancer. MEK inhibitors combined with nilotinib can overcome Drug resistance in chronic myelogenous leukemia (CML). Recent treatments for metastatic biliary tract cancer and control of low-grade serous ovarian or peritoneal cancer. Therefore, the MEK inhibitor selumetinib will become a new drug for the treatment of cancer.